GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>Seeing how in the past 12-16 months, the only course of management has been to get to the next dilution, they will not sleep even a tiny bit less over bad terms.<

I agree, and this is the reason I contemporaneously criticized the Ovation deal as suboptimal. Another $10-15M in up-front cash from that deal would have helped a lot right now.

>…the current [proposed] "bridge loan"- financing at 31 cents is a very striking example of how they view shareholder equity… ie just another means to get their goals across and no focus on revenue streams or short term cash.<

True—this management team has no qualms about dilution. If they had any spine, the BoD would have taken action by now to replace the people at the top.